Skip to content

Study for the value of detection of Candida-specific antibodies in early diagnosis of invasive candidiasis

Study for the value of detection of Candida-specific antibodies in early diagnosis of invasive candidiasis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022330
Enrollment
Unknown
Registered
2019-04-05
Start date
2019-04-01
Completion date
Unknown
Last updated
2019-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive candidiasis

Interventions

Gold Standard:Microscopic analysis of sterile material and blood culture or sterile tissue culture.
Index test:Candida-specific&#32

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with suspected invasive candidiasis are eligible for enrollment in the registry, if they meet the following criteria: at least 1 risk factor for invasive candidiasis and the clinical criteria. Risk factors invasive candidiasis include: Candida colonization, the administration of broad-spectrum antibiotic therapy, the presence of central vascular catheters, total parenteral nutrition, gastrointestinal or cardiac surgery, prolonged hospitalization, stay in ICU, burns, preterm birth, neutropenia, systemic application of glucocorticoid, HIV infection, diabetes. Clinical criteria include: Adequate antimicrobial therapy is ineffective or the fever is re-emerging, accompanied by elevated serological markers for bacterial infection (such as leukocyte count, neutrophil percentage, CRP, procalcitonin) and/or positive serum ß-D-glucan. And this episode is considered as suspected invasive candidiasis by clinical specialists.

Exclusion criteria

Exclusion criteria: Medical history not available (including uncertain risk factors and clinical manifestations not available)

Design outcomes

Primary

MeasureTime frame
Candida-specific antibodies;

Countries

China

Contacts

Public ContactRui Zheng

Shengjing Hospital of China Medical University

zhengr@sj-hospital.org+86 024 96615-21211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026